| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.33 | 3e-15 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.31 | 6e-14 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.23 | 7e-06 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.23 | 3e-05 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0002 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |